New Research & Development and Quality & Regulatory Executives Will
Help Company Move Sterility Assurance into the Future
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Verrix,
developer of solutions for rapid and accurate sterilization
confirmation, is expanding its leadership team in preparation for
commercialization of its EVA™ Biological Indicator (BI) System. Vice
President of Research & Development Kok-Hwee Ng, Ph.D., and Vice
President of Regulatory & Quality Aiying Sun will help advance the
company’s technology designed to protect patients from life-threatening
infections.
“Verrix is growing at a rapid pace as we prepare for commercialization
of the EVA BI System,” said Cameron Rouns, CEO of Verrix. “We are
excited to welcome Kok-Hwee and Aiying to the senior management group at
this pivotal time for the company. Their extensive expertise, proven
track record, and passion for emerging technology will be invaluable as
we introduce our first-to-market platform and continue our pipeline
development activities.”
Verrix was founded in 2013 to develop sterility assurance products and
technologies for the healthcare market and has doubled in size in the
last year. The company has a unique heritage—with foundational
technology originally invented and developed at NASA’s Jet Propulsion
Laboratory. The first BI system based on the advanced Verrix technology
is expected to be introduced in 2019.
“While medical technology has advanced in recent years, currently used
BI technology has not kept pace with evolving user needs,” Dr. Ng said.
“I look forward to working with Verrix to develop this novel technology
into a meaningful healthcare solution that addresses both the clinical
and operational challenges posed by healthcare-associated infections.”
Dr. Ng has more than two decades of leadership and management experience
in the medical device industry, working with both startup and Fortune
500 companies such as St. Jude Medical, Stryker, Boston Scientific,
Johnson & Johnson, Baxter International, General Electric Medical
Systems, and OrthoSensor.
Ms. Sun brings significant expertise in quality assurance and regulatory
affairs to the Verrix team. She has more than 25 years of experience
with medical device and pharmaceutical companies, working closely with
U.S. and international regulatory authorities to establish and
continuously improve quality management systems to ensure compliance
with applicable regulations and standards.
For full bios and to learn more about the Verrix leadership team, click here.
About Verrix
Verrix is a San Clemente, Calif.-based medical device company that is
using the most advanced technologies to help protect patients from
healthcare-associated infections. The foundational sterility assurance
technology, originally discovered at NASA’s Jet Propulsion Laboratory,
integrates cutting-edge optical physics, chemistry spectroscopy, and
molecular biology. Based on scientific expertise and close partnerships
with healthcare professionals, Verrix is developing market-changing
solutions for sterility assurance, environmental monitoring, and
infection control. Visit www.verrix.com
for more information.
Contacts
Media Contact
Andrea Sampson, Sullivan & Sampson PR
asampson@sullivanpr.com,
714/374-6174
Erin Manning, Vice President, Marketing, Verrix
erin.manning@verrix.com,
949/668-1229